Fiscal Period | 2024 |
---|---|
Period End Date | Sep 23 |
Revenue | 12192.41 |
Total Revenue | 12192.41 |
Costof Revenue Total | 2787.09 |
Gross Profit | 9405.32 |
Selling/ General/ Admin Expenses Total | 2364.36 |
Depreciation/ Amortization | 632.82 |
Unusual Expense( Income) | 0.00 |
Other Operating Expenses Total | 3827.49 |
Total Operating Expense | 9611.76 |
Operating Income | 2580.65 |
Interest Inc( Exp) Net- Non- Op Total | -833.80 |
Other Net | 293.61 |
Net Income Before Taxes | 2790.88 |
Provisionfor Income Taxes | 390.10 |
Net Income After Taxes | 2400.78 |
Minority Interest | -9.59 |
Equity In Affiliates | -156.80 |
Net Income Before Extra Items | 2375.51 |
Net Income | 2375.51 |
Income Availableto Com Excl Extra Ord | 2375.51 |
Income Availableto Com Incl Extra Ord | 2375.51 |
Diluted Net Income | 2375.51 |
Diluted Weighted Average Shares | 239.95 |
Diluted EPS Excluding Extra Ord Items | 9.90 |
DPS- Common Stock Primary Issue | 0.00 |
Diluted Normalized EPS | 9.90 |
Sun Pharmaceutical Industries Dividend | Sun Pharmaceutical Industries Bonus | Sun Pharmaceutical Industries News | Sun Pharmaceutical Industries AGM | Sun Pharmaceutical Industries Rights | Sun Pharmaceutical Industries Splits | Sun Pharmaceutical Industries Board Meetings | Sun Pharmaceutical Industries Key Metrics | Sun Pharmaceutical Industries Shareholdings | Sun Pharmaceutical Industries Profit Loss | Sun Pharmaceutical Industries Balance Sheet | Sun Pharmaceutical Industries Cashflow | Sun Pharmaceutical Industries Q1 Results | Sun Pharmaceutical Industries Q3 Results | Sun Pharmaceutical Industries Q4 Results
Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks